CN1090176A - 抗肾病综合症药物 - Google Patents

抗肾病综合症药物 Download PDF

Info

Publication number: CN1090176A
Authority: CN; China
Prior art keywords: carbon; spherical; group; under; syndrome
Prior art date: 1992-10-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN93119547A

Other languages

English (en)

Chinese (zh)

Inventor

伊势道仁

菅野三喜男

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Kureha Corp

Original Assignee

Kureha Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-29

Filing date

1993-10-29

Publication date

1994-08-03

1993-10-29 Application filed by Kureha Corp filed Critical Kureha Corp

1994-08-03 Publication of CN1090176A publication Critical patent/CN1090176A/zh

Status Pending legal-status Critical Current

Links

208000011580 syndromic disease Diseases 0.000 title abstract description 15
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 68
229910052799 carbon Inorganic materials 0.000 claims abstract description 42
206010029164 Nephrotic syndrome Diseases 0.000 claims abstract description 16
239000003814 drug Substances 0.000 claims abstract description 10
238000010521 absorption reaction Methods 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 4
230000000694 effects Effects 0.000 abstract description 7
239000004615 ingredient Substances 0.000 abstract description 7
150000003431 steroids Chemical class 0.000 abstract description 4
238000000034 method Methods 0.000 description 20
238000002360 preparation method Methods 0.000 description 11
210000002700 urine Anatomy 0.000 description 11
230000002378 acidificating effect Effects 0.000 description 9
239000011148 porous material Substances 0.000 description 8
230000037396 body weight Effects 0.000 description 7
239000002775 capsule Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000012298 atmosphere Substances 0.000 description 6
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
239000000243 solution Substances 0.000 description 6
RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
238000003763 carbonization Methods 0.000 description 5
239000007937 lozenge Substances 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
230000009467 reduction Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
230000004913 activation Effects 0.000 description 4
239000008187 granular material Substances 0.000 description 4
206010010774 Constipation Diseases 0.000 description 3
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
229960005205 prednisolone Drugs 0.000 description 3
230000008569 process Effects 0.000 description 3
239000002994 raw material Substances 0.000 description 3
RYSMHWILUNYBFW-UHFFFAOYSA-N 4-amino-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N(C)C)=NC=NC=2N1C1OC(CO)C(N)C1O RYSMHWILUNYBFW-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
238000002479 acid--base titration Methods 0.000 description 2
239000003245 coal Substances 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000012299 nitrogen atmosphere Substances 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
201000001474 proteinuria Diseases 0.000 description 2
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
WURBVZBTWMNKQT-UHFFFAOYSA-N 1-(4-chlorophenoxy)-3,3-dimethyl-1-(1,2,4-triazol-1-yl)butan-2-one Chemical compound C1=NC=NN1C(C(=O)C(C)(C)C)OC1=CC=C(Cl)C=C1 WURBVZBTWMNKQT-UHFFFAOYSA-N 0.000 description 1
229920000298 Cellophane Polymers 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
101000869659 Mus musculus Relaxin receptor 2 Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010039807 Secondary adrenocortical insufficiency Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000003570 air Substances 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
239000000729 antidote Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000005001 laminate film Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000009115 maintenance therapy Methods 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000002969 morbid Effects 0.000 description 1
108700011006 mouse mighty Proteins 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
150000003116 prednisolone derivatives Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
229950010131 puromycin Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
-1 steroid chemical compound Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000007669 thermal treatment Methods 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Inorganic Chemistry (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN93119547A 1992-10-29 1993-10-29 抗肾病综合症药物 Pending CN1090176A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP314180/92		1992-10-29
JP31418092A JP3518878B2 (ja)	1992-10-29	1992-10-29	抗ネフローゼ症候群剤

Publications (1)

Publication Number	Publication Date
CN1090176A true CN1090176A (zh)	1994-08-03

Family

ID=18050223

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN93119547A Pending CN1090176A (zh)	1992-10-29	1993-10-29	抗肾病综合症药物

Country Status (7)

Country	Link
EP (1)	EP0595715A1 (2)
JP (1)	JP3518878B2 (2)
KR (1)	KR970002613B1 (2)
CN (1)	CN1090176A (2)
AU (1)	AU657059B2 (2)
CA (1)	CA2108436A1 (2)
TW (1)	TW228473B (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1101193C (zh) *	1994-11-15	2003-02-12	吴羽化学工业株式会社	药物的肾毒性减轻剂
CN1615908B (zh) *	2003-10-22	2011-09-28	株式会社吴羽	口服给药用吸附剂、以及肾病治疗或预防剂、和肝病治疗或预防剂
CN1942196B (zh) *	2004-04-02	2012-09-26	株式会社吴羽	口服给药用吸附剂、肾病治疗或预防剂、及肝病治疗或预防剂
TWI587878B (zh) *	2015-12-22	2017-06-21		Oral toxic adsorbent

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6830753B2 (en)	2001-04-11	2004-12-14	Kureha Chemical Industry Co., Ltd.	Adsorbent for oral administration
EP1407772B9 (en) *	2002-10-09	2007-02-21	Kureha Corporation	Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases
US7651974B2 (en)	2002-11-01	2010-01-26	Kureha Chemical Industry Co., Ltd.	Adsorbent for oral administration
JP3672200B2 (ja) *	2002-11-01	2005-07-13	呉羽化学工業株式会社	経口投与用吸着剤
CA2504517C (en) *	2002-11-01	2008-08-12	Kureha Corporation	Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
JP3585043B2 (ja)	2003-01-22	2004-11-04	メルク・ホエイ株式会社	医薬用吸着剤及びその製法
TWI370012B (en)	2004-04-02	2012-08-11	Kureha Corp	Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
US20090181095A1 (en) *	2005-05-16	2009-07-16	Kureha Corporation	Oxidative stress inhibitor
JP2010208969A (ja) *	2009-03-09	2010-09-24	Kureha Corp	寿命延長剤
JP5984352B2 (ja)	2010-10-12	2016-09-06	フタムラ化学株式会社	経口投与用医薬用吸着剤の製造方法
JP7228498B2 (ja)	2018-10-24	2023-02-24	フタムラ化学株式会社	フェノール樹脂の製造方法
WO2020213559A1 (ja)	2019-04-16	2020-10-22	フタムラ化学株式会社	活性炭吸着剤の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5673542A (en) *	1979-11-22	1981-06-18	Kureha Chem Ind Co Ltd	Adsorbent
JPS59193826A (ja) *	1983-04-20	1984-11-02	Mochida Pharmaceut Co Ltd	経口投与用活性炭

1992
- 1992-10-29 JP JP31418092A patent/JP3518878B2/ja not_active Expired - Fee Related
1993
- 1993-06-26 TW TW082105094A patent/TW228473B/zh active
- 1993-09-23 AU AU47570/93A patent/AU657059B2/en not_active Ceased
- 1993-10-14 CA CA002108436A patent/CA2108436A1/en not_active Abandoned
- 1993-10-27 EP EP93402632A patent/EP0595715A1/en not_active Ceased
- 1993-10-28 KR KR1019930022561A patent/KR970002613B1/ko not_active Expired - Fee Related
- 1993-10-29 CN CN93119547A patent/CN1090176A/zh active Pending

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1101193C (zh) *	1994-11-15	2003-02-12	吴羽化学工业株式会社	药物的肾毒性减轻剂
CN1615908B (zh) *	2003-10-22	2011-09-28	株式会社吴羽	口服给药用吸附剂、以及肾病治疗或预防剂、和肝病治疗或预防剂
CN1942196B (zh) *	2004-04-02	2012-09-26	株式会社吴羽	口服给药用吸附剂、肾病治疗或预防剂、及肝病治疗或预防剂
TWI587878B (zh) *	2015-12-22	2017-06-21		Oral toxic adsorbent

Also Published As

Publication number	Publication date
AU657059B2 (en)	1995-02-23
CA2108436A1 (en)	1994-04-30
JP3518878B2 (ja)	2004-04-12
KR940008689A (ko)	1994-05-16
AU4757093A (en)	1994-05-12
TW228473B (2)	1994-08-21
EP0595715A1 (en)	1994-05-04
KR970002613B1 (ko)	1997-03-06
JPH06135841A (ja)	1994-05-17

Legal Events

Date	Code	Title
1994-07-27	C10	Entry into substantive examination
1994-07-27	SE01	Entry into force of request for substantive examination
1994-08-03	C06	Publication
1994-08-03	PB01	Publication
2000-09-06	C01	Deemed withdrawal of patent application (patent law 1993)
2000-09-06	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CA2504517C (en)	2008-08-12	Adsorbent for oral administration, and agent for treating or preventing renal or liver disease
JP3522708B2 (ja)	2004-04-26	経口投与用吸着剤
US6830753B2 (en)	2004-12-14	Adsorbent for oral administration
CA2113856C (en)	1998-05-26	Antidiabetic agent
US5573761A (en)	1996-11-12	Agent for reducing nephrotoxicity due to medicine
JP3518878B2 (ja)	2004-04-12	抗ネフローゼ症候群剤
Ho et al.	1983	Asthma associated with N-acetylcysteine infusion and paracetamol poisoning: report of two cases
EP0688566B1 (en)	2000-12-13	Use of spherical activated carbon for the treatment of hemorrhoidal diseases
CN113350525A (zh)	2021-09-07	一种多孔淀粉负载青蒿素羟丙基-β-环糊精包合物及其制备方法和应用
CN1432391A (zh)	2003-07-30	一种具有治疗和保健作用的中药组方
EP1797889A1 (de)	2007-06-20	Aktivkohle für die medizinische Verwendung
DE202006001770U1 (de)	2007-02-08	Aktivkohle für die medizinische Verwendung
Dawling et al.	1983	In vitro and in vivo evaluation of two preparations of activated charcoal as adsorbents of aspirin
DE60213819T2 (de)	2007-08-09	Pharmazeutische Zubereitung enthaltend poröse sphärische kohlenstoffhaltige Teilchen und deren Verwendung zur Behandlung von Leber- und Nierenerkrankungen
KR840001449B1 (ko)	1984-09-27	다공성 구상 탄소질 생성물의 제조방법
CN1454596A (zh)	2003-11-12	一种银杏叶提取物与双嘧达莫复方药物及其制备方法
Muirhead et al.	1942	The advantages and clinical uses of desiccated plasma prepared by the Adtevac process
AU2003204621B8 (en)	2010-04-22	Adsorbent for oral administration
WO1987006135A1 (en)	1987-10-22	Composition and method for reducing blood alcohol content
CN1457851A (zh)	2003-11-26	一种具有治疗和保健作用的中药组方
US20170290856A1 (en)	2017-10-12	Oral adsorbent and method for producing oral adsorbent
Vozza et al.	1990	The efficacy, safety and tolerance of ceftazidime for the treatment of bacterial infections in the elderly
CN106983745A (zh)	2017-07-28	叶绿素和/或其衍生物在制备用于预防和/或治疗铁过载的药物中的用途
CN1686374A (zh)	2005-10-26	一种参附冻干粉针剂的新制备方法

CN1090176A - 抗肾病综合症药物 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=18050223

Family Applications (1)

Country Status (7)

Cited By (4)

Families Citing this family (12)

Family Cites Families (2)

Cited By (4)

Also Published As

Similar Documents

Legal Events